One To Watch

Tortugas Neuroscience

A Framingham, Massachusetts, neuroscience company that launched in April 2026 with million and four clinical-stage small molecules in-licensed from Eisai and Jiangsu Hansoh; its schizophrenia drug obuprazine posted positive Phase IIb data in October 2026.

Company Overview

US biotech company Tortugas Neuroscience develops small-molecule drugs for brain disorders, and it has skipped the usual discovery years. It launched in April 2026 with $106 million and a ready-made clinical pipeline of four assets in-licensed from Eisai of Japan and Jiangsu Hansoh Pharmaceutical Group of China, covering schizophrenia, tinnitus, focal epilepsy and reversible encephalopathies. The bet is that mechanisms already understood in the clinic, taken into large and well-defined indications, can reach approval faster than new biology. The first test of that bet came in October 2026, when obuprazine, its schizophrenia drug, beat placebo at every dose in a 363-patient Phase IIb trial run in China by its licensor. The company is run by two former Sage Therapeutics executives.


Headquarters and Global Presence

Tortugas is headquartered in Framingham, Massachusetts. Its licensing partners are in Japan and China, and the company has said its mid-stage clinical trials are planned in the USA.


Founding and History

Tortugas grew out of Cure Ventures, the venture firm founded in 2021 that builds companies from scratch. Al Robichaud, a Cure partner, was part of the team that assembled the neuroscience portfolio behind it. The company launched publicly on April 21, 2026, and it takes its name from the turtle, which it uses as a symbol of patient, careful research.


Therapy Areas and Focus

Tortugas works in neurology and neuropsychiatry, and it has picked indications with large patient populations and well-defined regulatory paths. Schizophrenia is the biggest of them. Tinnitus, the persistent perception of sound with no external source, is one of the less crowded areas in CNS drug development. Focal epilepsy is a large market in which a new mechanism has to show an advantage over many existing drugs. Reversible encephalopathies, brain dysfunction that can in principle be undone, are the most specialized target. The company says it is also evaluating additional patient populations for each asset.


Technology Platforms and Modalities

Every program is a small-molecule new chemical entity, and Tortugas intends each to be a once-daily oral drug. The company does not run a discovery platform in the usual sense; its method is selection. It in-licenses compounds with known mechanisms, clinical and translational data already in hand, and differentiated pharmacology, then develops them through focused trials. The four mechanisms span dopamine and serotonin receptors, the GABA-A receptor, the GAT-1 GABA transporter and the PDE9 enzyme.


Key Pipeline and Programs

Obuprazine (TRTL-107), for schizophrenia, is a partial agonist at dopamine D2/D3 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors, a profile in the family of established antipsychotics. In a Phase IIb trial run by Hansoh in 363 hospitalized Chinese adults with acute schizophrenia, all three dose ranges beat placebo on the Positive and Negative Syndrome Scale total score at day 42, the 1.5-3.0mg group by 16.7 points, and Tortugas now plans a US Investigational New Drug application. TRTL-913 is a positive allosteric modulator of the GABA-A receptor for tinnitus. A Phase II study is registered with a September 2026 start and is not yet recruiting; Part A tests TRTL-913 in healthy volunteers and Part B in adults with tinnitus, against placebo. TRTL-729 is an uncompetitive GAT-1 inhibitor for focal epilepsy, and a single-dose Phase I study of a new tablet formulation in healthy volunteers is also registered for September 2026. TRTL-118 is a PDE9 inhibitor aimed at reversible encephalopathies. According to STAT, the schizophrenia and tinnitus drugs came from Jiangsu Hansoh and the focal epilepsy and encephalopathy drugs from Eisai. The launch financing is meant to carry the two lead candidates through Phase II. A discovery-stage program is undisclosed.


Recent Developments

On October 12, 2026 Tortugas reported that obuprazine (TRTL-107) met the primary endpoint of a Phase IIb trial in schizophrenia, run by licensor Hansoh in 363 hospitalized Chinese adults. Every dose beat placebo on the Positive and Negative Syndrome Scale total score at day 42, the drug was numerically ahead of aripiprazole, and discontinuations for adverse events were about 2.1% against 2.5% on placebo. These are Chinese data, so the next step is Tortugas' own US Investigational New Drug application. September built the finance team for it: Jim Frates of Amylyx Pharmaceuticals joined the board, and Ramzi Benamar, finance chief of Bellus Health through its sale to GSK, became chief financial officer.


Key Personnel

Jeff Jonas, chief executive, is a partner at Cure Ventures and was previously chief executive of Sage Therapeutics; earlier he ran Shire's regenerative medicine division. Al Robichaud, president and head of research and development, was the founding scientist and chief scientific officer at Sage, where the team developed Zulresso (brexanolone) and Zurzuvae (zuranolone). Ramzi Benamar is chief financial officer, and Chad Beyer heads research.


Strategic Partnerships

The pipeline rests on two in-licensing deals, with Eisai and Jiangsu Hansoh, whose financial terms have not been disclosed. Tortugas holds rights to obuprazine everywhere except Greater China, which stays with Hansoh, the drug's original developer and the sponsor of the Phase IIb trial and earlier studies. Cure Ventures led the seed round and co-led the Series A with The Column Group and AN Venture Partners, a Tokyo and San Francisco firm that links Japanese science to US start-ups.


FAQ Section

US biotech company Tortugas Neuroscience develops small-molecule drugs for brain disorders, and it has skipped the usual discovery years. It launched in April 2026 with $106 million and a ready-made clinical pipeline of four assets in-licensed from Eisai of Japan and Jiangsu Hansoh Pharmaceutical Group of China, covering schizophrenia, tinnitus, focal epilepsy and reversible encephalopathies. The bet is that mechanisms already understood in the clinic, taken into large and well-defined indications, can reach approval faster than new biology.

Obuprazine (TRTL-107), for schizophrenia, is a partial agonist at dopamine D2/D3 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors, a profile in the family of established antipsychotics. In a Phase IIb trial run by Hansoh in 363 hospitalized Chinese adults with acute schizophrenia, all three dose ranges beat placebo on the Positive and Negative Syndrome Scale total score at day 42, the 1.5-3.0mg group by 16.7 points, and Tortugas now plans a US Investigational New Drug application. TRTL-913 is a positive allosteric modulator of the GABA-A receptor for tinnitus. A Phase II study is registered with a September 2026 start and is not yet recruiting; Part A tests TRTL-913 in healthy volunteers and Part B in adults with tinnitus, against placebo.

On October 12, 2026 Tortugas reported that obuprazine (TRTL-107) met the primary endpoint of a Phase IIb trial in schizophrenia, its first clinical readout. In 363 Chinese adults hospitalized with acute schizophrenia, every dose cut the Positive and Negative Syndrome Scale total score more than placebo at day 42, led by the 1.5-3.0mg group at 16.7 points, and Tortugas plans to file a US Investigational New Drug application. In September it named Ramzi Benamar chief financial officer and added Jim Frates, chief financial officer of Amylyx Pharmaceuticals, to the board.

Tortugas works in neurology and neuropsychiatry, and it has picked indications with large patient populations and well-defined regulatory paths. Schizophrenia is the biggest of them. Tinnitus, the persistent perception of sound with no external source, is one of the less crowded areas in CNS drug development. Focal epilepsy is a large market in which a new mechanism has to show an advantage over many existing drugs. Reversible encephalopathies, brain dysfunction that can in principle be undone, are the most specialized target.

Every program is a small-molecule new chemical entity, and Tortugas intends each to be a once-daily oral drug. The company does not run a discovery platform in the usual sense; its method is selection. It in-licenses compounds with known mechanisms, clinical and translational data already in hand, and differentiated pharmacology, then develops them through focused trials. The four mechanisms span dopamine and serotonin receptors, the GABA-A receptor, the GAT-1 GABA transporter and the PDE9 enzyme.

Jeff Jonas, chief executive, is a partner at Cure Ventures and was previously chief executive of Sage Therapeutics; earlier he ran Shire's regenerative medicine division. Al Robichaud, president and head of research and development, was the founding scientist and chief scientific officer at Sage, where the team developed Zulresso (brexanolone) and Zurzuvae (zuranolone). Ramzi Benamar is chief financial officer, and Chad Beyer heads research.

The pipeline rests on two in-licensing deals, with Eisai and Jiangsu Hansoh, whose financial terms have not been disclosed. Tortugas holds rights to obuprazine everywhere except Greater China, which stays with Hansoh, the drug's original developer and the sponsor of the Phase IIb trial and earlier studies. Cure Ventures led the seed round and co-led the Series A with The Column Group and AN Venture Partners, a Tokyo and San Francisco firm that links Japanese science to US start-ups.

Want to Update your Company's Profile?


More Tortugas Neuroscience news >